OncoMatch/Clinical Trials/NCT06220162
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
Is NCT06220162 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies chidamide in combination with venetoclax and azacitidine (VAC) for acute myeloid leukemia.
Treatment: chidamide in combination with venetoclax and azacitidine (VAC) — Chidamide in combination with venetoclax and azacitidine (VAC) were expected to improve remission rate of patients following to VA regimen treatment failure.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: ABL1 fusion
Excluded: BCR fusion
Allowed: FLT3 mutation
Performance status
ECOG 2–3(Limited self-care)
Demographics
Prior therapy
Must have received: VA regimen
Patients with AML who failed to respond to VA regimen
Cannot have received: radiotherapy
Not received radiotherapy...within 4 weeks prior to enrolment
Cannot have received: treatment regimens other than the VA regimen
Not received...treatment regimens other than the VA regimen...within 4 weeks prior to enrolment
Cannot have received: haematopoietic stem cell transplantation
Not received...haematopoietic stem cell transplantation within 4 weeks prior to enrolment
Cannot have received: chidamide (chidamide)
With prior treatment with chidamide
Lab requirements
Kidney function
creatinine clearance ≥ 30 ml/min to < 45 ml/min
Liver function
moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0 x upper limit of normal (uln)
Cardiac function
presence of a cardiac history of congestive heart failure, or ejection fraction ≤ 50%, or presence of chronic stable angina
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06220162 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy, treatment regimens other than the VA regimen, haematopoietic stem cell transplantation disqualifies patients from enrollment.
Are patients with ABL1 alterations eligible?
No. ABL1 fusion is an exclusion criterion.
Are patients with BCR alterations eligible?
No. BCR fusion is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages